---
# For vignette -----------------------------------------------------------------
title: "Apply: Sigmoid Model -- KOR Antagonists"
subtitle: Analysis of Four Kappa Opioid Receptor Antagonists
description: Demonstrate the applying a sigmoid model electrophysiology data
# Document ---------------------------------------------------------------------
output: rmarkdown::html_vignette
vignette: >
  %\VignetteIndexEntry{Apply: Sigmoid Model -- KOR Antagonists}
  %\VignetteKeyword{BayesPharma}
  %\VignetteEngine{knitr::rmarkdown}
  %\VignetteEncoding{UTF-8}
  %\VignetteDepends{drc}

---






### Hill Equation {#sec-hill}

In this case study, we are going to reanalyze the dose responses of 4
Kappa Opioid receptor (KOR) antagonists from a study performed by Margolis et
al. (-@Margolis2020-bm) using the `BayesPharma`
package. Whole cell electrophysiology in acute rat
midbrain slices was used to evaluate the pharmacological properties of
four novel KOR antagonists: BTRX-335140, BTRX-395750, PF-04455242, and
JNJ-67953964.

Originally, the dose-response analysis was performed using
the `drc` package in R, which implements the minimization of negative
log likelihood function and reduces to least square estimation for a
continuous response. The data were normalized to % baseline agonist response,
measuring the extent of blockade of agonist response in the presence of
different concentrations of antagonist. These data were then fit to a 4-parameter
log-logistic dose response model, setting the top (max agonist response) to
100% and estimating the IC50, its variance, and the bottom (min agonist
response).

#### Fitting the sigmoid model

Using the `BayesPharma` package, we can re-fit the sigmoid model with a
negative slope, and fix the top parameter to `100` as the response is
normalized to a no-antagonist baseline.

For the prior, we are going to use a normal distribution because the
response values are continuous. First, we will run the analysis with the
`top` (max response) parameter prior set to a constant value of `100`
because `top` is normalized to `100` and is the default broad prior for the `ic50`,
`hill`, and `bottom` parameters. Broad priors represent unbiased uncertainty and
provide an opportunity for extreme responses.

The level of informativeness of the prior will affect how much
influence the prior has on the model. Here is more [information on
prior choice
recommendations.](https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations)

\scriptsize

``` r
kor_prior <- BayesPharma::sigmoid_antagonist_prior(top = 100)
kor_prior
##            prior class coef group resp dpar  nlpar   lb   ub source
##  normal(-6, 2.5)     b                        ic50 <NA> <NA>   user
##    normal(-1, 1)     b                        hill <NA> 0.01   user
##    constant(100)     b                         top <NA> <NA>   user
##   normal(0, 0.5)     b                      bottom <NA> <NA>   user
```
\normalsize

#### Prior predictive checks
Following the Bayesian workflow, before fitting the model, it is good to check
the prior predictive distributions to see if they are compatible with the domain
expertise. So, before running the model, we will verify that the prior
distributions cover a plausible range of values for each parameter. To do this,
we want to  sample only from the prior distributions by adding
`sample_prior = "only"` as  an argument to the `sigmoid_model`
function. We will use the default response distribution of the model
(`family = gaussian()`).



\scriptsize

``` r
kor_sample_prior <- BayesPharma::sigmoid_model(
  data = kor_antag |> dplyr::select(substance_id, log_dose, response),
  formula = BayesPharma::sigmoid_antagonist_formula(),
  prior = kor_prior,
  init = BayesPharma::sigmoid_antagonist_init(),
  sample_prior = "only")
```
\normalsize

And then plot of the prior predictive distributions:

\scriptsize

``` r
kor_sample_prior |>
  BayesPharma::plot_density_distribution()
```

<div class="figure" style="text-align: center">
<img src="apply_sigmoid_KOR_files/kor-prior-density-plot-1.png" alt="KOR antagonists prior distribution" width="100%" />
<p class="caption">KOR antagonists prior distribution</p>
</div>
\normalsize

To sample from the model, we will use the `Stan` NUTs Hamiltonian Monte
Carlo, and initialize the parameters to the prior means to help with
model convergence, using the default values of `ec50 = -9`, `hill = -1`,
`top = 100`, `bottom = 0`.

\scriptsize

``` r
kor_model <- BayesPharma::sigmoid_model(
  data = kor_antag |> dplyr::select(substance_id, log_dose, response),
  formula = BayesPharma::sigmoid_antagonist_formula(
    predictors = 0 + substance_id), 
  prior = kor_prior,
  init = BayesPharma::sigmoid_antagonist_init())
```
\normalsize

#### Analyzing model fit

The `brms` generated model summary shows the formula that the expected
response a is sigmoid function of the `log_dose` with four parameters, and
a shared Gaussian distribution. Each parameter is dependent on the
`substance_id`. Since we want to fit a separate model for each substance, we
include a `0 +` to indicate that there is no common intercept. The data
consists of `73` data points and the posterior sampling was done in `4`
chains each with `8000` steps with `4000` steps of warm-up. The population
effects for each parameter summarize the marginal posterior distributions,
as well as the effective sample size in the bulk and tail. This gives
an indication of the sampling quality, with an ESS of > `500` samples
being good for this type of model.

\scriptsize

```
##  Family: gaussian 
##   Links: mu = identity; sigma = identity 
## Formula: response ~ sigmoid(ic50, hill, top, bottom, log_dose) 
##          ic50 ~ 0 + substance_id
##          hill ~ 0 + substance_id
##          top ~ 0 + substance_id
##          bottom ~ 0 + substance_id
##    Data: data (Number of observations: 73) 
##   Draws: 4 chains, each with iter = 8000; warmup = 4000; thin = 1;
##          total post-warmup draws = 16000
## 
## Regression Coefficients:
##                                Estimate Est.Error l-95% CI u-95% CI Rhat Bulk_ESS Tail_ESS
## ic50_substance_idBTRX_335140      -8.84      0.20    -9.20    -8.42 1.00    15027     8248
## ic50_substance_idBTRX_395750      -8.24      0.41    -8.93    -7.36 1.00    11072     5925
## ic50_substance_idJNJ              -9.15      0.31    -9.77    -8.50 1.00    15946    10770
## ic50_substance_idPF               -6.14      1.08    -7.69    -3.32 1.00     7646     5332
## hill_substance_idBTRX_335140      -1.47      0.59    -2.85    -0.57 1.00    14309     9824
## hill_substance_idBTRX_395750      -0.91      0.52    -2.28    -0.26 1.00    10745     7238
## hill_substance_idJNJ              -1.01      0.51    -2.38    -0.41 1.00    14567    11520
## hill_substance_idPF               -0.31      0.24    -0.92    -0.03 1.00     7908     5627
## bottom_substance_idBTRX_335140    -0.00      0.49    -0.96     0.95 1.00    17746    11293
## bottom_substance_idBTRX_395750     0.01      0.50    -0.97     0.99 1.00    18472    10902
## bottom_substance_idJNJ            -0.01      0.49    -0.99     0.96 1.00    17703    11821
## bottom_substance_idPF              0.01      0.50    -0.97     0.99 1.00    16850    11426
## top_substance_idBTRX_335140      100.00      0.00   100.00   100.00   NA       NA       NA
## top_substance_idBTRX_395750      100.00      0.00   100.00   100.00   NA       NA       NA
## top_substance_idJNJ              100.00      0.00   100.00   100.00   NA       NA       NA
## top_substance_idPF               100.00      0.00   100.00   100.00   NA       NA       NA
## 
## Further Distributional Parameters:
##       Estimate Est.Error l-95% CI u-95% CI Rhat Bulk_ESS Tail_ESS
## sigma    32.17      2.90    27.13    38.38 1.00    14788    11389
## 
## Draws were sampled using sampling(NUTS). For each parameter, Bulk_ESS
## and Tail_ESS are effective sample size measures, and Rhat is the potential
## scale reduction factor on split chains (at convergence, Rhat = 1).
```
\normalsize

**Traceplot**: The model ran without warning messages, meaning there were no parameter
value problems or MCMC conflicts. The bulk and tail ESS indicate high
resolution and stability. The R-hat for each parameter equals `1.00` and
the `traceplot` shows the chains mixed well, indicating the chains
converged.

\scriptsize

``` r
kor_model |>
  bayesplot::mcmc_trace()
```

<div class="figure" style="text-align: center">
<img src="apply_sigmoid_KOR_files/kor-model-traceplot-1.png" alt="plot of chunk kor-model-traceplot" width="100%" />
<p class="caption">plot of chunk kor-model-traceplot</p>
</div>
\normalsize

**Compare prior and posterior marginal distributions**: Displayed below is a
plot for the prior and posterior distributions of the parameters (prior is pink
and posterior is teal). This can be useful for comparing the density
distribution of the prior and posterior produced by the model:

\scriptsize

``` r
BayesPharma::plot_prior_posterior_densities(
  model = kor_model,
  title_label = "")
```

<div class="figure" style="text-align: center">
<img src="apply_sigmoid_KOR_files/kor-model-prior-posterior-densities-1.png" alt="KOR antagonists model, compare prior and posterior distributions for each substance" width="100%" />
<p class="caption">KOR antagonists model, compare prior and posterior distributions for each substance</p>
</div>
\normalsize

Displayed below is a plot of the posterior distributions for each
parameter with the confidence intervals and mean. This is a useful
visual of the model results and can highlight the mode and high-density
intervals:
  
\scriptsize

``` r
BayesPharma::plot_posterior_density(
  kor_model,
  title_label = "")
## Error in `dplyr::filter()`:
## ℹ In argument: `!...`.
## Caused by error in `.data[[".variable"]]`:
## ! Column `.variable` not found in `.data`.
```
\normalsize

Displayed below is a plot of a sample of 100 sigmoid dose-response
curves from the posterior distribution (purple) and the median
quantile intervals:

\scriptsize

``` r
BayesPharma::plot_posterior_draws(
  model = kor_model,
  title = "")
```

<div class="figure" style="text-align: center">
<img src="apply_sigmoid_KOR_files/kor-model-posterior-draws-1.png" alt="KOR antagonists, posterior draws" width="100%" />
<p class="caption">KOR antagonists, posterior draws</p>
</div>
\normalsize

#### Comparing alternative models

To test the sensitivity of the analysis to the prior, we can re-fit the model
with a more informative prior:

\scriptsize

```
##              prior class coef group resp dpar  nlpar   lb   ub source
##  normal(-8.5, 0.5)     b                        ic50 <NA> <NA>   user
##    normal(-1, 0.5)     b                        hill <NA> 0.01   user
##      constant(100)     b                         top <NA> <NA>   user
##     normal(10, 15)     b                      bottom <NA> <NA>   user
```
\normalsize

Re-fitting the model with the `kor_prior2` gives:



\scriptsize

```
##  Family: gaussian 
##   Links: mu = identity; sigma = identity 
## Formula: response ~ sigmoid(ic50, hill, top, bottom, log_dose) 
##          ic50 ~ 0 + substance_id
##          hill ~ 0 + substance_id
##          top ~ 0 + substance_id
##          bottom ~ 0 + substance_id
##    Data: data (Number of observations: 73) 
##   Draws: 4 chains, each with iter = 8000; warmup = 4000; thin = 1;
##          total post-warmup draws = 16000
## 
## Regression Coefficients:
##                                Estimate Est.Error l-95% CI u-95% CI Rhat
## ic50_substance_idBTRX_335140      -8.82      0.21    -9.23    -8.37 1.00
## ic50_substance_idBTRX_395750      -8.58      0.31    -9.16    -7.94 1.00
## ic50_substance_idJNJ              -8.95      0.31    -9.53    -8.32 1.00
## ic50_substance_idPF               -8.18      0.45    -9.09    -7.30 1.00
## hill_substance_idBTRX_335140      -1.19      0.37    -1.99    -0.57 1.00
## hill_substance_idBTRX_395750      -1.06      0.39    -1.90    -0.42 1.00
## hill_substance_idJNJ              -0.85      0.33    -1.65    -0.39 1.00
## hill_substance_idPF               -0.72      0.45    -1.72    -0.07 1.00
## bottom_substance_idBTRX_335140     1.71     10.47   -19.21    21.94 1.00
## bottom_substance_idBTRX_395750    15.44     11.10    -7.30    36.02 1.00
## bottom_substance_idJNJ            -2.77      9.82   -23.22    15.35 1.00
## bottom_substance_idPF             31.22     11.59     7.03    52.03 1.00
## top_substance_idBTRX_335140      100.00      0.00   100.00   100.00   NA
## top_substance_idBTRX_395750      100.00      0.00   100.00   100.00   NA
## top_substance_idJNJ              100.00      0.00   100.00   100.00   NA
## top_substance_idPF               100.00      0.00   100.00   100.00   NA
##                                Bulk_ESS Tail_ESS
## ic50_substance_idBTRX_335140      13087    10643
## ic50_substance_idBTRX_395750      12995    10960
## ic50_substance_idJNJ              13299    11776
## ic50_substance_idPF               13156    10947
## hill_substance_idBTRX_335140      14798     9835
## hill_substance_idBTRX_395750      13437     9765
## hill_substance_idJNJ              13283    11670
## hill_substance_idPF                8776     5539
## bottom_substance_idBTRX_335140    14068    12061
## bottom_substance_idBTRX_395750    12671    10835
## bottom_substance_idJNJ            12510    10615
## bottom_substance_idPF             10495    10156
## top_substance_idBTRX_335140          NA       NA
## top_substance_idBTRX_395750          NA       NA
## top_substance_idJNJ                  NA       NA
## top_substance_idPF                   NA       NA
## 
## Further Distributional Parameters:
##       Estimate Est.Error l-95% CI u-95% CI Rhat Bulk_ESS Tail_ESS
## sigma    31.86      2.83    26.91    37.99 1.00    14470    11441
## 
## Draws were sampled using sampling(NUTS). For each parameter, Bulk_ESS
## and Tail_ESS are effective sample size measures, and Rhat is the potential
## scale reduction factor on split chains (at convergence, Rhat = 1).
```
\normalsize

**Comparing the Two Models Using LOO-Comparison**: One way to evaluate the
quality of a model is for each data-point, re-fit the model with remaining
points and evaluate the log probability of the point in the posterior
distribution. Taking the expectation across all points gives the Expected Log
Pointwise predictive Density (ELPD). Since this is computationally challenging
to re-fit the model for each point, if the model fits the data reasonably well,
then the ELPD can be approximated using the Pareto smoothed importance sampling
(PSIS). Using the LOO package, Pareto k value for each data point is computed
that indicate how well that data point is fit by the model, where `k < 0.5` is
good, `0.5 <= k < 0.7` is OK, and `0.7 <= k` is bad. Evaluating the model for
the KOR antagonists shows that the model fits the data well.

\scriptsize

```
## 
## Computed from 16000 by 73 log-likelihood matrix.
## 
##          Estimate   SE
## elpd_loo   -360.5  6.5
## p_loo         6.9  1.1
## looic       721.0 13.1
## ------
## MCSE of elpd_loo is 0.0.
## MCSE and ESS estimates assume MCMC draws (r_eff in [0.4, 1.4]).
## 
## All Pareto k estimates are good (k < 0.7).
## See help('pareto-k-diagnostic') for details.
```
\normalsize

Since ELPD is a global measure of model fit, it can be used to compare models.
Using `loo_compare` from the LOO package returns the `elpd_diff` and `se_diff`
for each model relative the model with the lowest ELPD. The `kor_model2`, the
model with more informative prior, is the preferred model, but not
significantly.

\scriptsize

```
## No problematic observations found. Returning the original 'loo' object.
##            elpd_diff se_diff
## kor_model2  0.0       0.0   
## kor_model  -0.9       1.2
```
\normalsize

**Comparing against models fit with the `drc` Package**:
Here we will analyze the KOR antagonist data using the `drc` package and
compare it to the results from the `BayesPharma` analysis.

We will fix the top to `100` and fit the `ic50`, `hill`, and
`bottom`.

\scriptsize

``` r
drc_models <- kor_antag |>
  dplyr::group_by(substance_id) |>
  dplyr::group_nest() |>
  dplyr::mutate(
    model = data |> 
      purrr::map(~drc::drm(
        response ~ log_dose,
        data = .x,
        fct = drc::L.4(fixed = c(NA, NA, 100, NA),
        names = c("hill", "bottom", "top", "ic50")))))

drc_models |>
  dplyr::mutate(summary = purrr::map(model, broom::tidy, conf.int = TRUE)) |>
  tidyr::unnest(summary) |>
  dplyr::arrange(term, substance_id) |>
  dplyr::select(-data, -model, -curve)
## # A tibble: 12 × 8
##    substance_id term   estimate std.error statistic  p.value  conf.low conf.high
##    <chr>        <chr>     <dbl>     <dbl>     <dbl>    <dbl>     <dbl>     <dbl>
##  1 BTRX_335140  bottom     1.31    19.4      0.0675 9.47e- 1  -40.0        42.6 
##  2 BTRX_395750  bottom    29.5      9.40     3.14   7.85e- 3    9.20       49.8 
##  3 JNJ          bottom   -18.1     26.7     -0.681  5.04e- 1  -73.7        37.4 
##  4 PF           bottom    39.4     30.8      1.28   2.22e- 1  -27.0       106.  
##  5 BTRX_335140  hill       4.06     9.20     0.441  6.65e- 1  -15.5        23.7 
##  6 BTRX_395750  hill       9.82   164.       0.0600 9.53e- 1 -344.        364.  
##  7 JNJ          hill       1.17     0.580    2.02   5.69e- 2   -0.0378      2.38
##  8 PF           hill       1.13     1.33     0.855  4.08e- 1   -1.73        4.00
##  9 BTRX_335140  ic50      -8.91     0.308  -28.9    1.42e-14   -9.57       -8.26
## 10 BTRX_395750  ic50      -8.97     0.505  -17.8    1.70e-10  -10.1        -7.88
## 11 JNJ          ic50      -8.77     0.670  -13.1    2.89e-11  -10.2        -7.37
## 12 PF           ic50      -7.96     1.27    -6.29   2.78e- 5  -10.7        -5.23
```
\normalsize

Displayed below is the comparison of results from `drc` and
`BayesPharma` for each parameter of the dose-response curve. Here we
see that the Bayesian method provides a distribution curve as evidence
and has smaller confidence intervals than most of the standard errors
provided by the `drc` method.



<div class="figure" style="text-align: center">
<img src="apply_sigmoid_KOR_files/kor-model-plot-vs-drc-1.png" alt="KOR antagonists conditional effects. The blue lines are samples from the `BayesPharma` kor_model posterior distribution, the orange line is the conditional mean, and the purple line is the conditional mean for the `drc` model fit." width="100%" />
<p class="caption">KOR antagonists conditional effects. The blue lines are samples from the `BayesPharma` kor_model posterior distribution, the orange line is the conditional mean, and the purple line is the conditional mean for the `drc` model fit.</p>
</div>

